Akoya Biosciences (AKYA) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Akoya Biosciences Revenue Highlights


Latest Revenue (Y)

$96.63M

Latest Revenue (Q)

$23.16M

Main Segment (Y)

Product

Main Geography (Y)

North America

Akoya Biosciences Revenue by Period


Akoya Biosciences Revenue by Year

DateRevenueChange
2023-12-31$96.63M29.09%
2022-12-31$74.86M36.31%
2021-12-31$54.92M29.39%
2020-12-31$42.44M0.49%
2019-12-31$42.24M-

Akoya Biosciences generated $96.63M in revenue during NA 2023, up 29.09% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Akoya Biosciences Revenue by Quarter

DateRevenueChange
2024-06-30$23.16M26.23%
2024-03-31$18.35M-30.72%
2023-12-31$26.49M5.04%
2023-09-30$25.21M7.20%
2023-06-30$23.52M9.86%
2023-03-31$21.41M0.90%
2022-12-31$21.22M12.56%
2022-09-30$18.85M5.35%
2022-06-30$17.89M5.92%
2022-03-31$16.89M4.56%
2021-12-31$16.16M19.90%
2021-09-30$13.48M3.10%
2021-06-30$13.07M7.03%
2021-03-31$12.21M-5.39%
2020-12-31$12.91M29.68%
2020-09-30$9.95M16.29%
2020-06-30$8.56M-22.33%
2020-03-31$11.02M-

Akoya Biosciences generated $23.16M in revenue during Q2 2024, up 26.23% compared to the previous quarter, and up 108.19% compared to the same period a year ago.

Akoya Biosciences Revenue Breakdown


Akoya Biosciences Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21
Product$67.41M$57.65M$44.48M
Consumables$24.13M$18.38M$14.30M
Instruments$42.09M$38.63M$28.69M
Service And Other$18.93M--
Standalone software products$1.18M$636.00K$1.49M
Service and other$29.22M$17.21M$10.44M

Akoya Biosciences's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (36.84%), Instruments (23.01%), Service and other (15.97%), Consumables (13.19%), Service And Other (10.35%), and Standalone software products (0.65%).

Quarterly Revenue by Product

Product/ServiceMar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
Instruments$4.87M$21.21M$11.28M$9.61M$11.14M$9.51M$9.46M$8.52M$8.50M$7.10M$6.26M$6.84M
Standalone software products$270.00K$924.00K$52.00K$205.00K$39.00K$200.00K$203.00K$194.00K$409.00K---
Product$12.14M$34.74M$17.15M$15.52M$15.71M$14.44M$14.16M$13.34M$12.92M$10.87M$10.72M$9.96M
Service and other$6.21M$16.96M$6.37M$5.89M$5.51M$4.41M$3.73M$3.55M$3.24M---
Consumables$7.00M$12.60M$5.82M$5.71M$4.53M$4.72M$4.50M$4.63M$4.01M$3.43M$4.31M$2.54M
Service And Other$3.38M-----------
Standalone Software Products---------$345.00K$151.00K$582.00K
Service---------$2.60M$2.35M$2.25M

Akoya Biosciences's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (35.84%), Consumables (20.67%), Service and other (18.33%), Instruments (14.37%), Service And Other (9.99%), and Standalone software products (0.80%).

Akoya Biosciences Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21
APAC$16.55M$15.06M$12.53M
North America$58.28M$42.05M$28.03M
EMEA$21.80M$17.75M$14.36M

Akoya Biosciences's latest annual revenue breakdown by geography, as of Dec 23: North America (60.31%), EMEA (22.56%), and APAC (17.13%).

Quarterly Revenue by Country

CountryMar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
APAC$3.27M$8.06M$4.11M$4.39M$3.47M$3.81M$4.27M$3.51M$3.00M---
North America$10.12M$32.62M$13.81M$11.85M$12.32M$10.92M$9.48M$9.32M$9.02M$7.39M$6.40M$5.21M
EMEA$4.96M$11.02M$5.60M$5.17M$5.43M$4.12M$4.14M$4.06M$4.13M---
Asia Pacific---------$2.83M$3.01M$3.69M
E M E A---------$3.25M$3.66M$3.31M

Akoya Biosciences's latest quarterly revenue breakdown by geography, as of Mar 24: North America (55.17%), EMEA (27.01%), and APAC (17.82%).

Akoya Biosciences Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
COOCooper Companies$3.59B$1.00B
ATRAptarGroup$3.49B$909.29M
ICUIICU Medical$2.26B$596.46M
HAEHaemonetics$1.31B$336.17M
ATRCAtriCure$399.25M$115.91M
ANGOAngioDynamics$303.91M$67.49M
LMATLeMaitre Vascular$193.48M$55.85M
AKYAAkoya Biosciences$96.63M$23.16M
PDEXPro-Dex$53.84M$14.89M
UTMDUtah Medical Products$50.22M$10.40M
ATRIAtrion-$48.77M

AKYA Revenue FAQ


Akoya Biosciences's yearly revenue for 2023 was $96.63M, representing an increase of 29.09% compared to 2022. The company's yearly revenue for 2022 was $74.86M, representing an increase of 36.31% compared to 2021. AKYA's yearly revenue for 2021 was $54.92M, representing an increase of 29.39% compared to 2020.

Akoya Biosciences's quarterly revenue for Q2 2024 was $23.16M, a 26.23% increase from the previous quarter (Q1 2024), and a -1.52% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $18.35M, a -30.72% decrease from the previous quarter (Q4 2023), and a -14.29% decrease year-over-year (Q1 2023). AKYA's quarterly revenue for Q4 2023 was $26.49M, a 5.04% increase from the previous quarter (Q3 2023), and a 24.83% increase year-over-year (Q4 2022).

Akoya Biosciences's revenue growth rate for the last 3 years (2021-2023) was 75.96%, and for the last 5 years (2019-2023) was 128.79%.

Akoya Biosciences's revenue streams in c 23 are Product, Consumables, Instruments, Service And Other, Standalone software products, and Service and other. Product generated $67.41M in revenue, accounting 36.84% of the company's total revenue, up 16.93% year-over-year. Consumables generated $24.13M in revenue, accounting 13.19% of the company's total revenue, up 31.31% year-over-year. Instruments generated $42.1M in revenue, accounting 23.01% of the company's total revenue, up 8.96% year-over-year. Service And Other generated $18.93M in revenue, accounting 10.35% of the company's total revenue Standalone software products generated $1.18M in revenue, accounting 0.65% of the company's total revenue, up 85.69% year-over-year. Service and other generated $29.22M in revenue, accounting 15.97% of the company's total revenue, up 69.81% year-over-year.

For the fiscal year ending Dec 23, the largest source of revenue of Akoya Biosciences was Product. This segment made a revenue of $67.41M, representing 36.84% of the company's total revenue.